Plethora Solutions Holdings plc: Fortacin™ is the first EU approved prescription treatment for premature ejaculation (“PE”) that does not act on the central nervous system. The treatment is a topical spray containing low doses of lidocaine and prilocaine that take effect almost immediately upon application, giving users more control without reducing pleasure. Plethora / Regent has recently entered into a license agreement with a wholly owned subsidiay of Shanghai Fosun Pharmaceuticals for $38M upfront and royalties that range from low to high-teens after hitting certain milestones related to the PRC roll-out. Based on Fosun’s estimates Fortacin™ has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, rising to over 170 million patients by its tenth year. The rights to Fortacin™ for Europe, Turkey, Russia and certain countries of North Africa were out-licensed to Recordati and commercial sales started in middle of 2018 in Italy, Germany, France, Portugal and Spain. Recordati will roll out Fortacin™ in the UK and other European countries in 2019.
Sector/industry:
Biotech Company
Characteristics:
Based in...
Europe
Clinical Stage
Marketed
Disease Space
Men's Health, Urology
Finance
Revenues
Industry
Specialty Pharmaceutical
Listing
Public
Market Cap
<100MM
Website:
Address:
Hampden House, Monument Business Park
Warpsgrove Lane
Chalgrove, Oxfordshire, OX44 7RW
UK

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.